Abstract
This study investigates symptom associations in SARS-CoV-2 positive individuals based on vaccination status. Unvaccinated individuals exhibited significantly higher odds of experiencing severe symptoms, including fever > 38.5□°C (logOR = 3.64, 95% CI: 1.52–5.77, p = 0.0008), rhinitis (logOR = 2.94, 95% CI: 0.82–5.05, p = 0.0065), headache (logOR = 2.17, 95% CI: 0.06–4.28, p = 0.0436), and myalgia (logOR = 3.25, 95% CI: 1.17–5.34, p = 0.0023). Conversely, unvaccinated individuals were less likely to report cough (logOR = -2.44, 95% CI: -4.53 to -0.34, p = 0.0226), potentially reflecting behavioral factors related to vaccine hesitancy. Among vaccinated participants, symptom profiles varied by vaccine type. Both Oxford-AstraZeneca and Pfizer-BNT162b2 vaccines were associated with increased odds of loss of smell (logOR = 0.81 and 1.47, respectively) and loss of taste (logOR = 0.75 for Oxford-AstraZeneca). Additionally, the Oxford-AstraZeneca vaccine was linked to dyspnea (logOR = 0.85, 95% CI: 0.02–1.69, p = 0.0449). These findings suggest that vaccination reduces the likelihood of severe systemic and respiratory symptoms while influencing specific symptom manifestations in breakthrough cases. Ongoing research is essential to understand vaccine-specific immune responses and their impact on clinical outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Council for Scientific and Technological Development (CNPq, Brazil) [152071/2020-2], the Tess Research Foundation (TRF, USA), [Early-Career Investigator Research Grant 2022/2023], the Carlos Chagas Filho Research Support Foundation of the State of Rio de Janeiro (FAPERJ) [Emergencial E-26/211.041/2021 and JCNE E-26/201.434/2021].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the University of Grande Rio (CEP/UNIGRANRIO), under CAAE number 32362220.1.0000.5283, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.